慢性乙型肝炎低病毒血症的研究现状  

Research status of low-level viremia in chronic hepatitis B

作　　者：孟娟 孙密密 MENG Juan;SUN Mimi(Hepatology and Infectious Diseases Department,Tai’an 88 Hospttal,271000,China)

机构地区：[1]泰安八十八医院肝病感染科,271000

出　　处：《传染病信息》2024年第6期550-554,共5页Infectious Disease Information

摘　　要：研究证实,规律接受一线核苷(酸)类似物治疗48周的慢性乙型肝炎患者,虽然其血清HBV DNA水平降低到2000 IU/mL以下,但仍持续或间歇性地高于检测下限,即处于低病毒血症(low-level viremia,LLV)状态,而LLV患者仍存在发展为肝纤维化、肝硬化、肝癌甚至其他终末期肝病的风险,严重威胁患者的生命健康,因此LLV已成为当下抗HBV治疗的热点及难点。目前尚无强有力的循证医学证据来指导LLV患者的治疗,并且缺乏相关的专家指南和共识。本文对一线核苷(酸)类似物经治慢性乙型肝炎患者LLV的研究现状进行综述,旨为此类患者的诊疗提供参考。Studies have confirmed that patients with chronic hepatitis B,regularly treated with first-line nucleoside(acid)analogues for 48 weeks,exhibit a reduction in serum HBV DNA to less than 2000 IU/mL,yet still persistently or intermittently higher than the lower limit of detection,indicating a state of low-level viremia(LLV).However,patients with LLV still have the risk of developing liver fibrosis,cirrhosis,liver cancer and even other end-stage liver diseases,which seriously threaten the life and health of patients.Therefore,LLV has become a hot and difficult point of antiviral therapy.At present,there is no strong evidence-based medicine treatment for LLV patients,and lack of relevant expert guidelines,consensus and other guidance.This article intends to review the research status of first-line nucleoside(acid)analogues in the treatment of LLV in patients with chronic hepatitis B,in order to provide reference for the diagnosis and treatment of such patients.

关 键 词：慢性乙型肝炎 低水平病毒血症 核苷(酸)类似物 

分 类 号：R512.91[医药卫生—内科学] R759.1[医药卫生—临床医学]